Skip to main navigation menu Skip to main content Skip to site footer

Drug induced cardiotoxicity: long QT syndrome with arrhythmogenic potential

Cardiotoxicidad inducida por fármacos: síndrome de QT prolongado con potencial arritmogénico




Section
Review Articles

How to Cite
Bello Benavides, L. A. (2020). Drug induced cardiotoxicity: long QT syndrome with arrhythmogenic potential. Journal of Medicine and Surgery Repertoire, 29(1). https://doi.org/10.31260/RepertMedCir.v29.n1.2020.865

Dimensions
PlumX
license

   

Ligia Alejandra Bello Benavides

    The use of drugs that prolong the QT interval is associated with increased risk of cardiac arrhythmias, especially torsades de pointe s (TdP) type polymorphic ventricular tachycardia, leading to long hospital stays, consultation to emergency services or even death. Thus, knowing about these drugs is important to prevent this type of reactions even before prescription. This review focuses on commonly used drugs that prolong the QT interval and may induce TdP in the hospital as well as in the outpatient setting, mechanisms of QT drug-induced prolongation, pre-disposing risk factors, prevention interventions and management for these arrhythmias. The drugs inducing prolonged QT must be identified and duly studied by the hospital staff as well as the outpatient clinic staff to prevent adverse reactions.

    Article visits 1072 | PDF visits 2061


    Downloads

    Download data is not yet available.
    1. Schwartz PJ, Woosley RL. Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes. J Am Coll Cardiol. 2016;67(13):1639-50. doi: 10.1016/j.jacc.2015.12.063.
    2. Vlachos K, Georgopoulos S, Efremidis M, Sideris A, Letsas KP. An update on risk factors for drug-induced arrhythmias. Expert Rev Clin Pharmacol. 2016;9(1):117-27. doi: 10.1586/17512433.2016.1100073.
    3. Wisniowska B, Tylutki Z, Wyszogrodzka G, Polak S. Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials. BMC Pharmacol Toxicol. 2016;17:12. doi: 10.1186/s40360-016-0053-1.
    4. Villamañán E, Armada E, Ruano M. Prolongación del intervalo QT inducido por fármacos: ¿conocemos sus riesgos? Medicina Clínica. 2015;144(6):269-74.
    5. Turker I, Ai T, Itoh H, Horie M. Drug-induced fatal arrhythmias: Acquired long QT and Brugada syndromes. Pharmacol Ther. 2017;176:48-59. doi: 10.1016/j.pharmthera.2017.05.001.
    6. Poluzzi E, Raschi E, Diemberger I, De Ponti F. Drug-Induced Arrhythmia: Bridging the Gap Between Pathophysiological Knowledge and Clinical Practice. Drug Saf. 2017;40(6):461-4. doi: 10.1007/s40264-017-0529-y.
    7. Lee A, Pickham D. Basic Cardiac Electrophysiology and Common Drug-induced Arrhythmias. Crit Care Nurs Clin North Am. 2016;28(3):357-71. doi: 10.1016/j.cnc.2016.04.007.
    8. Konstantopoulou A, Tsikrikas S, Asvestas D, Korantzopoulos P, Letsas KP. Mechanisms of drug-induced proarrhythmia in clinical practice. World J Cardiol. 2013;5(6):175-85. doi: 10.4330/wjc.v5.i6.175.
    9. Ng TM, Olsen KM, McCartan MA, Puumala SE, Speidel KM, Miller MA, et al. Drug-induced QTc-interval prolongation in the intensive care unit: incidence and predictors. Journal of pharmacy practice. 2010;23(1):19-24.
    10. doi: 10.1177/0897190009356549.
    11. Roden DM. Drug-induced prolongation of the QT interval. The New England journal of medicine. 2004;350(10):1013-22. doi: 10.1056/NEJMra032426.
    12. Drug and Therapeutics Bulletin. QT interval and drug therapy. BMJ. 2016;353:i2732. doi: 10.1136/bmj.i2732.
    13. Manini AF, Nair AP, Vedanthan R, Vlahov D, Hoffman RS. Validation of the Prognostic Utility of the Electrocardiogram for Acute Drug Overdose. Journal of the American Heart Association. 2017;6(2). doi:
    14. 1161/JAHA.116.004320.
    15. Hoogstraaten E, Rijkenberg S, van der Voort PH. Corrected QT-interval prolongation and variability in intensive care patients. Journal of critical care. 2014;29(5):835-9. doi: 10.1016/j.jcrc.2014.05.005.
    16. Ackerman MJ, Priori SG, Dubin AM, Kowey P, Linker NJ, Slotwiner D, et al. Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent? Heart rhythm. 2017;14(1):e41-e4. doi: 10.1016/j.hrthm.2016.09.012.
    17. Passman R, Kadish A. Polymorphic ventricular tachycardia, long Q-T syndrome, and torsades de pointes. The Medical clinics of North America. 2001;85(2):321-41. doi: 10.1016/s0025-7125(05)70318-7.
    18. Kaufman ES. Mechanisms and clinical management of inherited channelopathies: long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, and short QT syndrome. Heart rhythm. 2009;6(8 Suppl):S51-5. doi: 10.1016/j.hrthm.2009.02.009.
    19. Khan IA. Long QT syndrome: diagnosis and management. American heart journal. 2002;143(1):7-14. doi: 10.1067/mhj.2002.120295.
    20. Gringut S. Short QT Syndrome. In: Ferri FF, editor. Ferri's Clinical Advisor 2018. Philadelphia: Elsevier; 2018. p. 1174-5.e1.
    21. Avci A, Yilmaz A, Celik M, Demir K, Keles F. Successful treatment of suicide attempt by megadose of propafenone and captopril. Cardiovascular toxicology. 2013;13(3):230-3.
    22. Ari ME, Ekici F. Brugada-Phenocopy Induced by Propafenone Overdose and Successful Treatment: A Case Report. Balkan medical journal. 2017;34(5):473-5. doi: 10.4274/balkanmedj.2016.1185.
    23. Bayes de Luna A, Brugada J, Baranchuk A, Borggrefe M, Breithardt G, Goldwasser D, et al. Current electrocardiographic criteria for diagnosis of Brugada pattern: a consensus report. Journal of electrocardiology. 2012;45(5):433-42.
    24. Thomas SH, Behr ER. Pharmacological treatment of acquired QT prolongation and torsades de pointes. British journal of clinical pharmacology. 2016;81(3):420-7. doi: 10.1111/bcp.12726.
    25. Pourmand A, Mazer-Amirshahi M, Chistov S, Sabha Y, Vukomanovic D, Almulhim M. Emergency department approach to QTc prolongation. The American journal of emergency medicine. 2017;35(12):1928-33.
    26. Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC. 2016;149(3):139-52. doi: 10.1177/1715163516641136.
    Sistema OJS 3.4.0.5 - Metabiblioteca |